Latest Regulatory News

Echelon Resources has signed a term sheet with the Northern Territory’s Power and Water Corporation to supply gas through 2034, including plans for four new wells that could significantly increase output from the Amadeus Basin.

Radiopharm Theranostics reports promising interim Phase 2b results for RAD 101, achieving 92% concordance with MRI in detecting brain metastases, paving the way for a pivotal study in 2026.

Embark Early Education has successfully completed a $12 million placement to support its conditional takeover bid for Mayfield Childcare. The capital raise attracted strong backing from existing and new sophisticated investors.

The ASX has suspended trading of Olympio Metals and Thorney Technologies shares due to delayed periodic report filings, highlighting ongoing compliance challenges for both companies.

Diatreme Resources has submitted the Draft Environmental Impact Statement for its Northern Silica Project, marking a significant step toward regulatory approval and highlighting its potential to boost regional economies and support global solar energy growth.

Biotron Limited’s BITO securities have been suspended from ASX trading due to non-compliance with key listing rules, raising questions about the company’s next steps.

EV Resources is set to begin a fully funded maiden diamond drilling program at its high-grade Los Lirios antimony project in Mexico, aiming to define a maiden JORC resource by Q3 2026. This marks a pivotal step toward production readiness and a broader 2026 exploration campaign.

Prescient Therapeutics has secured European authorization to initiate a Phase 2a clinical trial of its novel cancer drug PTX-100 for relapsed/refractory Cutaneous T-cell Lymphoma, enabling trial site activation in Italy.

Nova Minerals Limited has voluntarily suspended trading of its shares on the ASX pending a capital raising announcement expected on 17 December 2025.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Neuren Pharmaceuticals’ partner Acadia secures FDA approval for DAYBUE STIX, a new powder formulation of trofinetide offering greater flexibility for Rett syndrome patients. This milestone expands treatment options and sets the stage for increased royalty revenue in 2026.

Fortifai Limited has acquired an exclusive license to Nol8, a breakthrough real-time data processing technology developed by the Technion. This acquisition positions Fortifai to revolutionize data handling across gaming, AI, finance, and cybersecurity sectors.